# ALG.APV-527

Source: https://onco.cc/drugs/alg-apv-527/  
OnCo record `alg-apv-527` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ALG.APV-527 is an antibody-like protein from Aptevo Therapeutics that switches on immune cells only where it finds a marker on tumour cells. It is being tested in several kinds of solid tumour.

## Summary

ALG.APV-527 is a 4-1BB x 5T4 bispecific candidate built on Aptevo Therapeutics' ADAPTIR platform. Aptevo's August 2026 filing states that it is designed to reactivate antigen-primed T cells to kill tumour cells and is being evaluated clinically in multiple solid tumour types; the filing does not state the phase.

## Fields

- Kind: Treatment
- Last checked: 2026-11-04
- Tags: pipeline
- Code: ALG.APV-527
- Modality: Bispecific antibody (4-1BB x 5T4)
- Mechanism: Binds the co-stimulatory receptor 4-1BB on T cells and the tumour antigen 5T4, designed to reactivate antigen-primed T cells at the tumour, as described by Aptevo Therapeutics.

## Sources

- SEC: Aptevo Therapeutics Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1671584/000119312526361103/apvo-20260821.htm

## Connected records

- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- targets: [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/)
- companies: [Aptevo Therapeutics](https://onco.cc/companies/aptevo-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/alg-apv-527.json